Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cardiac Biomarker Study in Esophageal Cancer Patients Treated With Chemotherapy and Radiation

Withdrawn

Conditions: Esophageal Cancer

Interventions: Other: Cardiac Biomarker Blood Draws

First Posted Date: 2012-06-25

Last Posted Date: 2014-07-28

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01627080

Imaging Study Compare 4DCT Image

Phase 1

Completed

Conditions: Lung Cancer
Esophagus Cancer

Interventions: Procedure: 4D CT scans

First Posted Date: 2012-06-22

Last Posted Date: 2015-11-18

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 52

Registration Number: NCT01626001

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers

Phase 1

Completed

Conditions: Advanced Malignant Neoplasm
Metastatic Malignant Neoplasm
Recurrent Malignant Neoplasm
Refractory Malignant Neoplasm

Interventions: Biological: Anakinra
Biological: Denosumab
Drug: Everolimus

First Posted Date: 2012-06-21

Last Posted Date: 2021-02-25

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 57

Registration Number: NCT01624766

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome

Phase 2

Recruiting

Conditions: Aplastic Anemia
de Novo Myelodysplastic Syndrome
Myelodysplastic Syndrome
Previously Treated Myelodysplastic Syndrome

Interventions: Biological: Anti-Thymocyte Globulin
Drug: Cyclosporine
Biological: Filgrastim
Drug: Methylprednisolone
Biological: Pegfilgrastim

First Posted Date: 2012-06-21

Last Posted Date: 2025-04-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 140

Registration Number: NCT01624805

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy

Not Applicable

Completed

Conditions: Spinal Tumor

Interventions: Radiation: Spinal SBRT (Higher Dose)
Radiation: Spinal SBRT (Standard Dose)
Procedure: Gold Seed Implantation
Behavioral: Questionnaires

First Posted Date: 2012-06-20

Last Posted Date: 2023-12-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 41

Registration Number: NCT01624220

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

NK Cells in Cord Blood Transplantation

Phase 1

Conditions: Acute Lymphoblastic Leukemia in Remission
Myelodysplastic Syndrome
Recurrent Acute Lymphoblastic Leukemia
Recurrent Non-Hodgkin Lymphoma
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
DS Stage III Plasma Cell Myeloma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
ISS Stage III Plasma Cell Myeloma
Acute Biphenotypic Leukemia
Recurrent Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine Phosphate
Drug: Cyclophosphamide
Other: Laboratory Biomarker Analysis
Drug: Lenalidomide
Drug: Melphalan
Drug: Mycophenolate Mofetil
Biological: Natural Killer Cell Therapy
Biological: Rituximab
Drug: Tacrolimus
Procedure: Umbilical Cord Blood Transplantation
Radiation: Total-Body Irradiation

First Posted Date: 2012-06-14

Last Posted Date: 2020-02-11

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT01619761

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

An Open-Label Phase II Study of the Combination of GSK2118436 and GSK1120212 in Patients With Metastatic Melanoma Which is Refractory or Resistant to BRAF Inhibitor

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: GSK2118436
Drug: GSK1120212

First Posted Date: 2012-06-14

Last Posted Date: 2016-12-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT01619774

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

Recruiting

Conditions: Leukemia
Lymphoma

Interventions: Behavioral: Focus Group
Other: Internet-Based Intervention
Behavioral: Interview

First Posted Date: 2012-05-30

Last Posted Date: 2025-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT01608152

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Study of Curcumin, Vorinostat, and Sorafenib

Phase 1

Withdrawn

Conditions: Advanced Cancers

Interventions: Drug: Curcumin
Drug: Sorafenib
Drug: Vorinostat

First Posted Date: 2012-05-30

Last Posted Date: 2012-10-19

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT01608139

A Mixed-Methods Approach to Understanding Factors Associated With Cervical Cancer Screening Utilization Among Low-Income, HIV-Positive Women

Completed

Conditions: Cancer Prevention
Cervix

Interventions: Behavioral: Cognitive Interview
Behavioral: Questionnaires
Behavioral: Focus Groups

First Posted Date: 2012-05-25

Last Posted Date: 2016-03-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 188

Registration Number: NCT01605656

Locations: 🇺🇸
Thomas Street Health Center, Harris County Hospital District, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy